Medulloblastomas are highly malignant neuroectodermal cerebellar tumors of children. One of the reasons for the difficulty for the treatment of medulloblastomas is their inherent tendency to metastasize through the cerebrospinal fluid (CSF) pathway leading to leptomeningeal dissemination. Recently, genetically modified neural stem cells (NSCs) were shown to have the capability of selectively migrating into glioma mass and delivering therapeutic agents with significant therapeutic benefits. In the present study, we applied the NSC strategy to target medulloblastomas, particularly their leptomeningeal dissemination. We used NSCs that were retrovirally transduced with the cytosine deaminase gene (CD-NSCs). In vitro studies demonstrated that CD-NSCs had sufficient migratory activity toward medulloblastoma cells and exerted a remarkable bystander effect on these cells following the application of 5-fluorocytosine (5-FC). It is noteworthy that neutralization of the hepatocyte growth factor blocked their migration In animal studies using our leptomeningeal dissemination model, CD-NSCs implanted directly into CSF space were shown to distribute diffusely within the disseminated tumor cells and could provide remarkable antitumor effect after intraperitoneal administration of 5-FC. Furthermore, CD-NSC treatment followed by 5-FC administration prolonged survival periods significantly in experimental animals. Our data suggest that the CD-NSC strategy can also be applied to target leptomeningeal dissemination of medulloblastomas.
Introduction
Medulloblastomas are highly malignant and invasive brain tumors that are preferentially manifested in children. Medulloblastomas are predominantly located in the cerebellar vermis and have an inherent tendency to metastasize to other brain regions and leptomeninges via the cerebrospinal fluid (CSF). 1 Although advances in multimodality therapy with aggressive surgery, radiation and chemotherapy have led to dramatic improvement in the prognosis over the past decades, the 5-year survival rate still ranges from 50 to 70%. [2] [3] [4] In particular, leptomeningeal dissemination that results from metastases through the CSF space is thought to be one of the most hideous features of medulloblastomas and characterizes their malignant behavior. The CSF metastases appear as foci of nodular or diffuse contrast enhancement in the leptomeninges or on the ventricular surface in one-third of the patients at presentation. Dissemination relapse is often observed early in the course and is detected more frequently than local relapse. 5 In adults, although less commonly found, most relapses and recurrences are found to occur at distant sites in the neuroaxis despite the fact that the initial manifestation of the disease is mostly limited to the posterior fossa. 6 The presence of craniospinal dissemination has been reported to be one of the factors associated with poor prognosis. 7 Although radiotherapy has been accepted as the most effective postoperative treatment for medulloblastomas, an increase in the radiation dose can lead to significant neurocognitive sequelae, particularly in very young adults. 8 Therefore, an ideal treatment would be one that can selectively target the medulloblastoma cells without damaging the normal nervous parenchyma.
Neural stem cells (NSCs) have recently aroused a great deal of attention in the field of neurooncology as delivery vehicles of therapeutic genes. In addition to their multipotential capabilities that allow them to differentiate into three major types of central nervous system (CNS) cells, that is, neurons, astrocytes and oligodendrocytes, NSCs are also characterized by their remarkable capability to migrate through the brain. [9] [10] [11] This migration of NSCs is strongly directed toward pathologically altered tissues, and this property has the potential to be utilized for the treatment of various lesions, such as ischemic lesions, traumatized tissue, areas of inflammation and metastatic or primary brain tumors. 12 Recent studies have demonstrated that NSCs display extensive tropism for experimental glioma and distribute throughout the primary tumor bed and migrate together with widely outgrowing tumor microsatellites. 13, 14 Furthermore, in experimental glioma models, these gliomatracking NSCs can deliver agents having significant therapeutic benefits by expressing the genes that they carry. [13] [14] [15] [16] [17] [18] Based on these findings, NSC-based therapy has the potential to be a promising new therapeutic approach for the treatment of incurable malignant gliomas. However, to the best of our knowledge, medulloblastomas that show disseminative behavior have not yet been target tumors in studies that employed the NSC strategy.
The purpose of this study was to explore the possibility of extending the gene-modified NSC strategy to the treatment of medulloblastomas with the expectation that the migratory ability of NSCs can be useful, particularly in the case of leptomeningeal disseminations, which represent a progressive and refractory state. In this study, we used NSCs that were transduced with the cytosine deaminase (CD) gene, which is a therapeutic suicide gene. CD is an enzyme that transforms the inert prodrug 5-fluorocytosine (5-FC) into a toxic product 5-fluorouracil (5-FU). 19 This enzyme/prodrug system exerts the 'bystander effect' that leads to the death of unmodified tumoral cells that are adjacent to the genetically modified cells. 20 First, we evaluated whether CD-NSCs exhibit tropism for medulloblastoma cells and exert the bystander killing effect on them after in vitro exposure to 5-FC. Second, we established an experimental leptomeningeal dissemination model in mice and observed how intrathecally implanted CD-NSCs behave. Third, we evaluated whether CD-NSCs play a role in suppressing tumor growth and prolonging the survival of treated mice.
Results

NSCs selectively migrate to brain tumor cells in vitro
To examine whether NSCs are able to migrate to medulloblastoma cells, their migratory activity was evaluated using double-chamber dishes. We plated two types of medulloblastoma cell lines -Daoy and ONS76 -and two glioma cell lines -U87MG and U251MG -in the lower chamber as the target cells. The migratory activity of DiI-NSCs was compared with that of DiI-293 human embryonic kidney cells that served as the control. Consistent with the results of a previous report 21, 22 glioma cells significantly stimulated the migration of NSCs in comparison to the control. More importantly, two types of medulloblastoma cells also significantly enhanced the migratory activity (Figure 1a) .
Inactivation of HGF blocks the migratory activity of NSCs
As scatter factor/hepatocyte growth factor (SF/HGF) was reported to be an important chemoattractant for NSCs 21 and Daoy and ONS76 cells were shown to express higher levels of SF/HGF, 23 we performed a blocking assay in which a neutralizing monoclonal antibody was added to the media present in the lower chamber. The results showed that the inactivation of SF/HGF led to a reduction in the migratory activity in all four cell lines. In particular, the migration of NSCs to Daoy, U87MGand U251MG cells was significantly inhibited after blocking of SF/HGF via neutralizing antibody (Figure 1b) .
NSCs carrying the CD suicide gene induce apoptosis in neighboring medulloblastoma cells after treatment with prodrug 5FC
We confirmed whether the DiI-labeled F3. 
Implanted F3.CD cells diffusely intermixes with leptomeningeal disseminations of Daoy cells
The direct CSF route was used as the method for implanting F3.CD cells. To confirm the migratory capability of CD-NSCs, the entire spinal cord, including the lumbar portion, was investigated pathologically. As shown in Figure 3 , the DiI-F3.CD cells implanted into the subarachnoid space of the cisterna magna spread throughout the entire spine and distributed in the Daoy cell layers. It is noteworthy that the DiI-F3.CD cells reached the lumbar area that is located away from the injection site. Moreover, the DiI-F3.CD cells infiltrated the tumor cell layer and existed not only on the surface of the layer but also at deeper levels near the cord (Figure 3) . Hence, we concluded that the NSCs injected into the subarachnoid space were able to migrate and intermix sufficiently with leptomeningeally disseminated Daoy cells. 
F3.CD cells reduce tumor growth by inducing apoptosis
To ascertain the potent induction of suicide in vivo and the bystander effect associated with the CD gene after the administration of 5-FC, we performed pathological examinations of sections of the entire spine. In Daoy cell-implanted mice that received F3.CD cells but not the 5-FC treatment, thick tumor cell layers existed on the surface all along the spinal cord (Figure 4a-c) . The DiI-labeled cells still remained diffuse in the tumor layer (Figure 4d and e) and few TUNEL-positive cells were detected in the cell layers (Figure 4f ). On the other hand, animals that were treated with a course of 5-FC intraperitoneally (i.p.) injections for 10 consecutive days following DiI-F3.CD cell implantation had no thick layers of Daoy cells along the spinal cord, but rather small residual clusters of Daoy cells (Figure 4g -i, k, and m). TUNEL-positive cells were partially observed in the residual tumor masses (Figures 4l and n) . Based on these findings, we were able to confirm that F3.CD cells present in the subarachnoid space died after the 5-FC i.p. injection; subsequently, they suppressed tumor growth by inducing apoptotic cell death in the neighboring Daoy cells.
CD-NSCs exposed to 5-FC prolong the survival of Daoy-disseminated mice
To determine whether CD-NSC implantation followed by subsequent 5-FC i.p. injections can provide therapeutic benefits in vivo, the treatment was initiated 7 days after the inoculation of Daoy cells into the subarachnoid space. We 
Discussion
Our in vitro migration assay demonstrated that the induction of tropism NSCs by medulloblastoma cells is consistent with human glioma cell lines, U87MG and U251MG; these cells previously have been reported to enhance the migration of NSCs. 21, 22 These findings substantiated the potential of the NSC strategy for treating medulloblastomas.
There are several differences between gliomas and medulloblastomas in terms of their biological features as well as their clinical manifestations. Gliomas are preferentially manifested in cerebral hemispheres, and the origin of gliomas has for long been assumed to be fully differentiated glial cells. Recent advances in stem cell biology have suggested that cancer stem cells or progenitor cells can serve as the origin of neoplastic formation, and some genetic alterations such as those occurring in p53, RB, PTEN, MDM2 or epidermal growth factor receptor are associated with glioma malignancy. 24 On the other hand, medulloblastomas are a type of embryonal CNS tumor and are also categorized as neuroectodermal tumors. This malignant invasive tumor is believed to originate from the external granule cell layer of the cerebellum, and that is associated with its predominant occurrence in cerebellar vermis. Recent studies have shown that medulloblastomas arise through abnormalities in the sonic hedgehog developmental signaling pathways in a population of progenitor cells. [25] [26] [27] Other molecular genetic events such as the inactivation of the retinoblastoma tumor-suppressor gene (Rb) 27 or amplification of c-myc 28 and n-myc 29 have also been implicated in medulloblastoma pathogenesis. Medulloblastomas express high levels of neuronal markers such as neurofilament protein and are thought to have a direction/incline toward neural rather than glial lineage. 30 The results of our in vitro migration assay imply that these two different types of brain tumors can release some soluble factors that can promote NSC tropism. With regard to glioma cells, several factors produced by glioma cells, such as vascular endothelial factor 31 and CXCR4, 32 have been suggested to promote the tropism of NSCs. A previous study has indicated that SF/HGF is the most powerful chemoattractant released from glioma. 21 In the case of medulloblastomas, although the factors that promote the tropism of NSCs have not yet been identified, there is an interesting report that SF/ HGF plays an important role in the malignancy of medulloblastomas. 23 It has been known for long that SF/ HGF is a predominantly epithelial rather than mesenchymal stimulant, 33 and the medulloblastoma cell lines Daoy and ONS-76 used in this study expressed moderate to high levels of c-Met and SF/HGF compared with the levels observed in glioma cells. 23 We hypothesized that SF/HGF is one of soluble chemoattractant that promotes the tropism of NSCs. In this study, we showed that the removal of SF/HGF by using neutralizing antibodies in the culture significantly inhibited the migration of NSCs toward medulloblastoma cells. These results indicate that SF/HGF released from the medulloblastoma may play the role of a chemoattractant in tropism shown by medulloblastoma. In support of these observations, an earlier report had shown that NSCs had the capacity to target nonneural tumors such as prostate cancer and malignant melanoma. 22 From these findings, it In particular, the migration of NSCs to Daoy, U87MG and U251MG cells was significantly inhibited after SF/HGF blocking.
NSC-based gene therapy for disseminated medulloblastoma S Shimato et al appears that the NSCs are endowed with an extensive migratory capacity to seek out neoplastic lesions.
In our animal experiments, we focused on a leptomeningeal dissemination model because one of the major barriers to conventional treatment of medulloblastomas is their ability to metastasize throughout the cerebrospinal axis. Our procedure for establishing experimental models of leptomeningeal dissemination of medulloblastomas was reproducible and provided the desired animal models in which the tumor cells spread extensively and NSC-based gene therapy for disseminated medulloblastoma S Shimato et al diffusely along the spinal cord, forming layers; these models appear ideal for efficient evaluation of the behavior of implanted NSCs. Our method in which NSCs were implanted by direct injection into the subarachnoid space of the cisterna magna resulted in sufficient distribution of NSCs within the established tumor cell layers. To the best of our knowledge, such behavior of NSCs, present in the CSF, toward tumor cells has been demonstrated for the first time in the literature. It is noteworthy that NSCs reached the lumbar area, which was distant from the implantation site, and also appeared to infiltrate the tumor cell layers. These findings lead to the speculation that NSCs first spread in the CSF space in the floating state, attach to the surface of the tumor layer and then infiltrate the tumor mass. 
NSC-based
A previous study has showen in their intracranial glioma model that NSCs exhibited extensive tropism for gliomas via various routes such as direct implantation in the tumor bed, at a distant intracranial site, in the contralateral hemisphere, in ventricles and in a peripheral intravascular site. 13 A certain level of tropism of NSCs toward disseminated cells via the peripheral vein was expected, and we performed an experiment in which NSCs were implanted via the tail vein. However, the migration of NSCs to the disseminated cell layer was not sufficiently large and could not lead to therapeutic effects (data not shown). The method of direct implantation of stem cells into the CSF has also been explored for treating injured spinal cords or inflammatory diseases. [34] [35] [36] [37] There is an interesting report that bone marrow stromal cells migrate toward injured spinal cord tissue more efficiently via the CSF route than the intravenous route. 34 One reason for the difficulty in delivering NSCs to the CNS parenchyma via the intravenous route is suggested to be associated with the need to open the blood-brain barrier (BBB). 37 In our dissemination model, the tumor cells existed completely outside the central nerve axis and were less likely to progress to parenchymal invasion. This situation might have caused little BBB destruction and led to inaccessibility to the tumor cells via the intravenous route. On the contrary, implantation via the CSF route provided free accessibility of the NSCs to the medulloblastoma cells, and this probably contributed to their remarkable distribution throughout the disseminated cells. For clinical applications, injection of NSCs by lumbar puncture appears to be more suitable because of its feasibility and safety. Such a modification of our method is justified by reports that the distribution of NSCs implanted into the CSF was observed to be equal, regardless of the injection site, that is, ventricles, cisterna magna or lumbar portion, in injured spinal cord models. 36 Various types of genetically modified NSCs such as those encoding cytotoxic compounds, immuneenhancing agents or apoptosis-promoting agents have been explored and were demonstrated to exhibit strong antitumor effects. [13] [14] [15] [16] [17] [18] The CD gene that was used in this study encodes the fungal and bacterial enzyme that catalyzes the deamination of nontoxic 5-FC into the highly toxic 5-FU. Further, cells expressing CD are killed following the prodrug administration. This so-called 'suicide gene' strategy for the treatment of malignant tumors depends on the bystander effect on surrounding cells. One of the advantages of using 5-FC in our dissemination model is that it is a small and highly water-soluble molecule and can penetrate well into most body sites, including the CSF. Another advantage is that this CD-5-FC strategy does not require cell-to-cell contact and connexin expression. 38, 39 Our study showed that the proliferation of medulloblastoma cells was markedly inhibited when a mixture of these cells with F3.CD cells was exposed to 5-FC that, in turn, led to the induction of apoptosis. These results are consistent with that reported previously in which it was shown that as little as 2% of the tumor mass containing CD-expressing cells may generate significant oncolysis in tumor. 40 In Figure 3 Implanted F3.CD cells distribute diffusely in leptomeningeal disseminations of Daoy cells. DiI-labeled F3 cells were injected into the subarachnoid space of the cisterna magna 15 days after the establishment of the dissemination models. After 2 days, the mouse was perfused with saline followed by 4% paraformaldehyde. The tissues were sectioned and stained with hematoxylin/eosin. DiI-F3 cells were identified in unstained sections by using fluorescence microscopy. It is noteworthy that the DiI-F3 cells reached not only cervical portion (a-f) but also lumbar area that was away from the injection site (g) and (h). Moreover, the DiI-F3 cells infiltrated into the tumor cell layer and existed not only on the surface of the layer but also at deeper levels near the cord. Magnification: Â 100, except for (e) and (f) ( Â 200).
NSC-based gene therapy for disseminated medulloblastoma S Shimato et al our animal experiments, the CD gene that was transduced in the NSCs functioned effectively and killed the surrounding Daoy human medulloblastoma cells by inducing apoptosis. It also exhibited remarkable tumor suppression. Furthermore, CD-NSC implantation followed by 5-FC administration led to significant prolongation of survival in animals as compared with the other treatment groups. Although these data strongly supported the antitumor effect of CD-NSC therapy, our experiments could reach disease-free only in an animal of seven. There should be ways to produce the maximum benefit. First, the proliferation of medulloblastoma cells could have been much greater than the bystander killing effect by CD-NSCs/5-FC. Initiating the treatment in an earlier state of dissemination, implanting larger amounts of CD-NSCs or repetition of the treatment may be more beneficial. Second, there was a possibility that 5-FU toxicity after 5-FC administration produced systemic effect. Experimental CD-gene therapy in rat prostate tumor models was reported to induce significant weight loss during 5-FC administration. 41 In our survival study, mice that were implanted with CD-NSCs and exposed to 5-FC exhibited a tendency to lose body weight earlier than those in the other treatment groups (data not shown). Therefore, appropriate measures to alleviate 5-FU toxicity must be considered for clinical application. In addition, this survival study suggested that NSCs alone could not provide survival benefits in our leptomeningeal dissemination models. NSCs or neural progenitor cells that have not been engineered were reported to have an innate ability to inhibit tumor outgrowth, 17, 42, 43 and some factors secreted from NSCs themselves have been suggested to control tumor cell proliferation. 42 The effect on the inhibition of tumor NSC-based gene therapy for disseminated medulloblastoma S Shimato et al growth by the neural progenitor cells themselves appeared to depend on the tumor cell profile such as the level of nestin expression. 42 This might be the reason why Daoy cells that express nestin are also resistant to NSCs.
Application of F3.CD cells in clinical applications raises some concerns. First, the immortalized human NSC cell line HB1.F3 that we used in this case has some drawbacks as it carries the potentially hazardous v-myc oncogene that might cause neoplasm formation in vivo once it is implanted in the animal brain. However, previous studies have shown no sign of transformation/ neoplasm formation in vitro or in vivo, 44 and we confirmed that mice in which only the F3 cells were transplanted into the subarachnoid space survived for more than 120 days without manifestation of body weight loss. Second, there are several technical and ethical concerns regarding the clinical use of NSCs, and these need to be addressed. Although autologous NSCs are ideal for clinical application, the acquisition of sufficient amounts of such NSCs is not possible at present time. Recently, mesenchymal stem cells have been reported to have the same migratory activity for glioma cells, and adenovival gene-modified MSCs were shown to be beneficial for the glioma-bearing animals. 45 Mesenchymal stem cells could be more feasible for clinical usage and might become alternative for NSCs.
We have demonstrated in in vitro studies that the human NSCs exhibited extensive tropism for medulloblastoma cells and that the CD-gene transduced in NSCs functioned effectively and had a remarkable bystander killing effect on medulloblastoma cells after 5-FC treatment. Using leptomeningeal dissemination mouse models, we confirmed that NSCs were able to distribute diffusely to medulloblastoma cells that had spread throughout the entire spinal cord after implantation in the cisterna magna and that the CD gene transduced in NSCs functioned effectively and killed the medulloblastoma cells by the bystander effect following administration of prodrug 5-FC. Moreover, treatment with CD-NSCs was beneficial in survival prolongation in tumor-bearing animals. These results offer a new promising therapeutic modality that uses human NSCs for targeting leptomeningeal dissemination of medulloblastomas.
Materials and methods
Cell lines
Daoy and ONS76 cells (human medulloblastoma cells), U87MG and U251MG cells (human glioma cells), and 293 cells (human embryonic kidney cells) were grown in Eagle's minimal essential medium (Nissui, Tokyo, Japan), containing 10% fetal bovine serum (FBS), 5 mM L-glutamine, 2 mM nonessential amino acids and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) at 371C in a humidified atmosphere of 5% CO 2 in air. The Daoy, U87MG, U251MG and 293 cells were obtained from the American Tissue Culture Collection (Mannasas, VA, USA), and the ONS76 cells were obtained from Dr K Shimizu (Kochi Medical College, Kochi, Japan).
NSCs
Immortalized human NSC line HB1.F3 (F3) were generated by transfection of fetal human telencephalon cells with a retroviral vector encoding the v-myc oncogene, as described previously. 44 This cell line is a clonally isolated, multipotent human NSC line and has been confirmed to have the ability to self-renew and differentiate into cells of the neuronal and glial lineages, both in vivo and in vitro. 44 In this study, F3 cells were transduced with a retroviral vector carrying a gene that encodes an oncolysis-promoting prodrug activation enzyme, that is the CD gene (F3.CD) (13) . F3.CD cells were cultured in Dulbecco's modified Eagle's medium with high glucose (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS, Fungizone (2.5 mg/ ml) and gentamicin (20 mg/ml).
DiI labeling of NSCs
F3.CD cells were prelabeled by adding CellTracker CM-DiI (Invitrogen) to the culture medium and incubating for 20 min. CM-DiI has maximum fluorescence emission at 570 nm, and the prelabeled CD-NSCs can be identified by fluorescence microscopy in which they appear to be red in color (DiI-F3.CD). They can also be distinguished from the nonlabeled cells by flow cytometry (FACSCalibur) with excitation at 488 nm under a 575/26 bandpass filter. NSC-based gene therapy for disseminated medulloblastoma S Shimato et al plates were incubated with serum-free medium for 24 h. All the cells in the lower chamber were then collected by trypsinization and resuspended in Hanks' balanced salt solution (Invitrogen). Flow cytometry was performed to measure the ratio of DiI-labeled cells to unlabeled cells. The migration of the F3.CD cells to the brain tumor cells was calculated according to the following formula: %migration ¼ (number of DiI-labeled cells/number of unlabeled cells) Â 100. For the blocking assay, a neutralizing monoclonal antibody against the (SF/HGF; R&D Systems, Minneapolis, MN, USA) was added to the media at a concentration of 20 mg/ml in the lower chamber under the same condition as that described above. The migratory rates were determined by the same method and compared with those of the control.
TUNEL staining
Twenty four hours after the Daoy cells (5 Â 10 4 cells) and DiI-F3.CD (5 Â 10 4 cells) were cocultured on a cover slip in a 35-mm dish, 5-FC was added to the conditioned medium at a concentration of 500 mg/ml and cultivation was continued for an additional 48 h. The cells were then rinsed twice with phosphate-buffered saline (PBS) and the adherent cells were fixed with 4% paraformaldehyde for 30 min. The cells that were fixed on the dishes were TUNEL-stained using the MEBSTAIN Apoptosis Kit II (MBL, Nagoya, Japan) in accordance with the manufacturer's instructions. Briefly, protease-treated sections were incubated with biotin-dUTP followed by avidinfluorescein isothiocyanate. The sections were then viewed under a fluorescence microscopy.
In vitro quantitative bystander effect assay
To quantify the bystander effect on Daoy cells as a result of F3.CD exposure to 5-FC, Daoy cells were seeded in a 24-well plate (2 Â 10 4 cells), and F3.CD cells were mixed with the Daoy cells in the same wells at various ratios ranging from 1:0 to 1:2. After 1 day, 5-FC was added at a final concentration of 500 mg/ml, and cultivation was continued for an additional 3 days. Each experiment was performed in triplicate. Cells were rinsed twice with PBS, and adherent cells were detached using trypsin/ethylenediaminetetraacetic acid. The number of viable cells was counted by the Trypan blue method and expressed as a percentage of the number of Daoy cells alone without any exposure to 5-FC.
Animal experiments Leptomeningeal dissemination model in mice. BALB/c female nude mice were anesthetized with an intraperitoneal injection of pentobarbital (60-70 mg/kg body weight). The head was fixed in a stereotactic guiding device, and the cisterna magna was exposed under the microscope. Daoy cells suspended in PBS at a concentration of 1.5 Â 10 6 cells per 30 ml were slowly injected into the subarachnoid space of the cisterna magna using a 30-gauge needle. The needle was slowly removed and the injection point was sealed with BD Matrigel Matrix (BD Biosciences, Franklin Lakes, NJ, USA). This leptomeningeal dissemination model was reproducible and had a survival of approximately 30-40 days. Histologically, Daoy cells diffusely disseminated within the subarachnoid space throughout the spinal cord down to the lumbar canal ( Figure 6 ).
Implantation of F3.CD
Fourteen days after the establishment of the medulloblastoma dissemination model, DiI-F3.CD cells suspended in PBS at a concentration of 5 Â 10 7 cells per 30 ml were injected into the same portion of the cisterna magna as that described in the procedure for the establishment of the dissemination model. After 2 days, the mice were perfused with saline followed by 4% paraformaldehyde under deep anesthesia. The entire spinal cord was then carefully dissected from the vertebral bones. The spinal cords were postfixed overnight with 4% paraformaldehyde and then equilibrated in PBS containing 30% sucrose for 48 h. The fixed spinal cords were embedded in the optimal cutting temperature compound (Miles Inc., Elkhart, IN, USA) and stored at À701C. The tissue was sectioned at 20 mm and stained with hematoxylin. DiI-F3.CD cells were identified in unstained sections by using fluorescence microscopy. were injected into the cisterna magna 10 days after the implantation of Daoy cells. After 2 days, 5-FC was injected i.p. at a dose of 900 mg/kg body weight daily for 10 consecutive days. The control mice received only saline. A day after the last 5-FC dose, the entire spinal cord was dissected in the same manner as that described above and postfixed overnight with 4% paraformaldehyde. It was then embedded in paraffin. The tissues were sectioned at 20 mm for histological examination, including hematoxylin/eosin staining, TUNEL staining and fluorescence microscopy.
For the survival experiments, animals were randomly divided into the following four groups 7 days after the implantation of Daoy cells: (A) the F3.CD/5-FC group in which mice were injected i.p. with 5-FC 2 days after F3.CD inoculation; (B) the F3.CD/saline group in which mice were injected i.p. with saline 2 days after F3.CD inoculation; (C) the 5-FC only group in which mice were injected with only 5-FC; and (D) the saline only group in which model mice were injected with only saline.
Statistical analyses
In the blocking assay, the statistical significance of the difference was determined by analysis of variance (StatView, SAS Institute, Cary, NC, USA) and Bonferroni's correction for multiple comparisons was employed. Survival curves were generated by the Kaplan-Meier method. The log-rank statistic (StatView) was used to compare the distribution of survival times. All reported P-values were two-sided and were considered to be statistically significant when they were below 0.05.
